UNSPSC 51292305: Mosapramine dihydrochloride

This classification denotes an antidepressant agent with the molecular formula C28H35ClN4O.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6M1W6HZL1X, chemically known as spiro(imidazo(1,2-a)pyridine-3(2h),4'-piperidin)-2-one, 1'-(3-(3-chloro-10,11-dihydro-5h-dibenz(b,f)azepin-5-yl)propyl)hexahydro-, hydrochloride (1:2), but more generally known as mosapramine dihydrochloride, which bears US NIH Compound Identifier 656595.

European Medicines Agency schedules mosapramine dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09073MIG. Most nations, for tariff purposes, schedule mosapramine dihydrochloride under HS 29333999. SMILES: C1CCC2C(C1)CCC3CCC(CC3N2CCCN4CCC5(CC4)C(=O)NC6N5CCCC6)CL.CL.CL.

UNSPSC 51292305 Mosapramine dihydrochloride is a Commodity code that in recent state and local procurement activity does not reflect purchasing aligned with the code's pharmaceutical name. The three most recent opportunities posted under or near this code involve naloxone distribution systems, direct-to-manufacturer prescription program design, and multi-source generic pharmaceuticals and OTC products—none of which are mosapramine-specific acquisitions. The mismatch suggests either tagging misalignment in the state and local procurement systems or that this code does not currently see active, relevant solicitation activity. County health departments, state health and human services agencies, and cooperative purchasing alliances are the issuing bodies appearing in recent records, but their actual procurement targets do not match the code's nominal scope.

Recent opportunities span Florida, Texas, and Minnesota. Seminole County, Florida posted an IFB (No. IFB60459723LAS) on June 30, 2026, for naloxone and drug deactivation systems with a response deadline of July 26, 2023 (an inconsistent date in the source). The Texas Health and Human Services Commission issued an RFI (No. HHS0017013) on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription programs. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, released an RFP (No. S1070000015802) on January 20, 2026, for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026. The code shows little relevant recent activity and the opportunities present do not reflect procurement of mosapramine dihydrochloride as a discrete product line.